Skip to main content

Table 3 Results of the gene mutations of gyrA and parC for selected strains from the different treatment groups, the minimal inhibitory concentration (MIC) values are also provided for these isolates with wild-type cut-off of 0.125 μg/mL. The silent mutations, i.e. polymorphisms in codon sequence resulting in the same amino acid, in gyrA and parC are given, with the reference sequences indicated in grey. Escherichia coli K12 MG1655 was used for reference

From: The impact of therapeutic-dose induced intestinal enrofloxacin concentrations in healthy pigs on fecal Escherichia coli populations

Isolate MIC (μg/mL) gyrA mutations parC mutations Silent mutations (gyrA/ parC) and additional resistance mechanisms
E. coli K12 MG1655 NA None None REFERENCE gyrA: 85GTC, 91CGC, 100TAT, 110TCT /parC: 91CAA
ATCC 25922™ 0.064 None None  
Y01.V2 – Group 1 – 0 h 0.064 None None  
Y08.V3 – Group 2 – 0 h 0.032 None None  
Y11.V2 – Group 3 – 0 h 0.016 None None  
Y12.V2 – Group 4 – 0 h 0.064 None None  
X02.V2 – Group 1 – 0 h 2.00 None None gyrA: 85GTT, 91CGT, 100TAC, 110TCC/ parC: 91CAG and qnrS1 positive
Y02.V2 – Group 2 – 0 h 4.00 None None gyrA: 85GTT, 91CGT, 100TAC, 110TCC/ parC: 91CAG and qnrS1 positive
X06.V2 – Group 2 – 0 h 4.00 None None gyrA: 85GTT, 91CGT, 100TAC, 110TCC/ parC: 91CAG and qnrS1 positive
Y09.V2 – Group 3 – 0 h 2.00 None None gyrA: 85GTT, 91CGT, 100TAC, 110TCC/ parC: 91CAG and qnrS1 positive
X12.V2 – Group 4 – 0 h 1.00 None None gyrA: 85GTT, 91CGT, 100TAC, 110TCC/ parC: 91CAG and qnrS1 positive
X04.V2 – Group 1 – 58 h > 32.00 83Leu, 87Asn 80Ile  
X07.V3 – Group 2 – 58 h > 32.00 None None  
X08.V4 – Group 2 – 58 h > 32.00 83Leu, 87Asn 80Ile  
X09. V4 – Group 2 – 58 h > 32.00 83Leu, 87Asn 80Ile  
X11.V6 – Group 3 – 58 h > 32.00 83Leu, 87Asn 80Ile  
X13.V1 – Group 4 – 58 h > 32.00 83Leu, 87Asn 80Ile  
X14.V1 – Group 4 – 58 h > 32.00 83Leu, 87Asn 80Ile  
X15. V1 – Group 4 – 58 h > 32.00 83Leu, 87Asn 80Ile  
  1. NA Not available